Skip to main content
Novo Nordisk takes on Lilly with newly approved diabetes drug
12/6/2017

Novo Nordisk's newly approved Ozempic will compete directly with Eli Lilly and Co.'s Trulicity in the diabetes drug market. The new drug will be priced at about $676 per prescription, which the company said is on par with other drugs in the class.

Full Story: